• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 483204 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1414673128 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1414673128 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Nektar Therapeutics: 52-Week High Recently Eclipsed (NKTR)

Published on Fri, 04/19/2013 - 14:16
By Peter Chu

Shares of Nektar Therapeutics (NASDAQ:NKTR) traded today at $11.34, breaking its 52-week high. So far today approximately 878,000 shares have been exchanged, as compared to an average 30-day volume of 834,000 shares.

Nektar Therapeutics (Nektar) is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain, anti-infectives, anti-viral and immunology. Nektar's research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient.

Nektar Therapeutics share prices have moved between a 52-week high of $11.34 and a 52-week low of $5.65 and are now trading 96% above that low price at $11.06 per share. Over the past week, the 200-day moving average (MA) has gone up 0.6% while the 50-day MA has advanced 1.6%.

There is potential upside of 8.5% for shares of Nektar Therapeutics based on a current price of $11.06 and an average consensus analyst price target of $12.00. The stock should discover initial support at its 50-day moving average (MA) of $10.03 and subsequent support at its 200-day MA of $8.87.

By Peter Chu
pchu@fnno.com

Latest News from FNNO

Possible Bearish Inside Day Candle Patte...

Analyzing the price chart for HEICO (NYSE:HEI) has revealed a potential bearish inside ...

Possible Bearish Inside Day Candle Patte...

Analysts have spotted a possible bearish inside day candle pattern in American Vanguard ...

Analysis of Relative Performance in the ...

Here are 5 stocks in the Trucking industry ranked by performance. We compiled the trad ...

Bottom 5 Companies in the Systems Softwa...

Here are 5 stocks in the Systems Software industry ranked by performance. We compiled ...

Analysis of Relative Performance in the ...

Analysis was conducted on the Steel industry to measure relative performance to find st ...

Shares of Office Depot Underperformed it...

Analysis was conducted on the Specialty Stores industry to measure relative performance ...

Analysis of Relative Performance in the ...

Below are five companies in the Specialty Chemicals industry that underperformed yester ...

Weyerhaeuser has Relatively Underperform...

Here are 5 stocks in the Specialized REITs industry ranked by performance. We compiled ...